A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro - PubMed (original) (raw)
A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro
Q Zhou et al. Clin Exp Immunol. 2008 Sep.
Abstract
XAGE-1b is regarded as one of the most immunogenic antigens and the most promising targets for lung adenocarcinoma immunotherapy. In this study, we sought to determine whether monocyte-derived dendritic cells (DCs) pulsed with purified full-length XAGE-1b could induce specific cytotoxic T lymphocytes (CTLs) against tumour cells from patients with non-small cell lung cancer (NSCLC) in vitro. XAGE-1b mRNA expression was examined in primary cultures of lung cancer cells and normal lung epithelial cells established from fresh tissues surgically resected from 30 patients with NSCLC using reverse transcription-polymerase chain reaction (RT-PCR). XAGE-1b mRNA expression was observed in 11 of 18 (61.1%) adenocarcinomas and one of 12 (8.3%) lung cancers of other histological types (P = 0.015). The 246-base pairs XAGE-1b gene was inserted into a recombinant expression vector. Full-length XAGE-1b was then expressed in BL21 (DE3) Escherichia coli and purified by AKTA-fast performance liquid chromatography (FPLC). DCs generated from peripheral blood mononuclear cells were pulsed with XAGE-1b by incubation with the protein at an immature stage. The XAGE-1b-pulsed DCs induced CTLs following 14 days of co-culture. Finally, an adherent target detachment (ATD) assay was performed to test the cytotoxicity of the XAGE-1b-specific CTLs against cancer cells and normal lung epithelial cells. The XAGE-1b-specific CTLs had a stronger lytic effect on autologous XAGE-1b mRNA-positive cancer cells than on autologous XAGE-1b mRNA-negative cancer cells or allogenous XAGE-1b mRNA-positive cancer cells. The CTLs had no lytic activity against normal lung epithelial cells. These results can be used to develop simple and effective cancer/testis antigen-based immunotherapies for NSCLC.
Figures
Fig. 1
XAGE-1b mRNA expression status in tumour tissues of 10 patients with non-small cell lung cancer. M, DNA marker; lanes 1, 5, 6, 9, 10, XAGE-1b mRNA expression positive; lanes 2, 3, 4, 7, 8, XAGE-1b mRNA expression negative.
Fig. 2
Restriction enzyme analysis and polymerase chain reaction (PCR) identification of recombinant vector B01/XAGE. M, DNA markers; lane 1, pReceiver-B01a expression vector; lane 2, restriction digest analysis of pReceiver-B01a using _Xmn_I and _Xho_I; lane 3, recombinant vector B01/XAGE; lane 4, restriction digest analysis of recombinant vector B01/XAGE using _Xmn_I and _Xho_I; lane 5, amplification of XAGE-1b by PCR using recombinant vector B01/XAGE as templates.
Fig. 3
Purification profile of recombinant XAGE-1b analysis by 18% sodium dodecyl sulphate–polyacrylamide gel electrophoresis before and after purification. Lane 1, supernatants of cell lysates in non-induced culture; lane 2, pellets of cell lysates in non-induced culture; lane 3, supernatants of cell lysates in induced culture; lane 4, pellets of cell lysates in induced culture; M, protein marker; lane 5, flow; lane 6, 20 mmol/l imidazole wash; lane 7, 50 mmol/l imidazole eluate; lane 8, 100 mmol/l imidazole eluate; lane 9, 200 mmol/l imidazole eluate; lane 10, 300 mmol/l imidazole eluate; lane 11, 500 mmol/l imidazole eluate.
Fig. 4
Immunofluorescence analysis of the XAGE-1b-pulsed dendritic cells (DCs). Intense fluorescence in the cytoplasm and membranes of mature XAGE-1b-pulsed DCs were observed under fluorescence microscope.
Fig. 5
Flow cytometric analysis of mature XAGE-1b-pulsed dendritic cells (DCs). High levels of CD86, CD40, human leucocyte antigen D-related, CD80 and CD83 were expressed on the mature XAGE-1b-pulsed DCs.
Fig. 6
Cytotoxicity of XAGE-1b-specific cytotoxic T lymphocytes (CTLs) against cancer cells and normal lung epithelial cells. Mean ± standard deviation from five patients. T lymphocytes co-cultured with mock-pulsed dendritic cells (DCs) were used as control effector cells. (a) XAGE-1b mRNA-positive autologous cancer cells were used as target cells; (b) XAGE-1b mRNA-negative autologous cancer cells were used as target cells; (c) normal lung epithelial cells were used as target cells; D, XAGE-1b mRNA-positive allogenous cancer cells were used as target cells with the XAGE-1b-specific CTLs.
Similar articles
- XAGE-1 expression in non-small cell lung cancer and antibody response in patients.
Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E. Nakagawa K, et al. Clin Cancer Res. 2005 Aug 1;11(15):5496-503. doi: 10.1158/1078-0432.CCR-05-0216. Clin Cancer Res. 2005. PMID: 16061866 - Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, Yano Y, Naito K, Kohara J, Nakane K, Matsuura Y, Takeda A, Takeda T, Kawai K, Yamagishi H. Imura K, et al. Int J Oncol. 2006 Sep;29(3):531-9. Int J Oncol. 2006. PMID: 16865268 - Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Ohue Y, et al. Int J Cancer. 2012 Sep 1;131(5):E649-58. doi: 10.1002/ijc.27359. Epub 2012 Jan 3. Int J Cancer. 2012. PMID: 22109656 - [Molecular biology of lung cancer series].
Hiret S, Senellart H, Bennouna J. Hiret S, et al. Rev Mal Respir. 2010 Oct;27(8):954-8. doi: 10.1016/j.rmr.2010.08.002. Rev Mal Respir. 2010. PMID: 20965409 Review. French. - Non-small-cell lung cancer vaccine therapy: a concise review.
O'Mahony D, Kummar S, Gutierrez ME. O'Mahony D, et al. J Clin Oncol. 2005 Dec 10;23(35):9022-8. doi: 10.1200/JCO.2005.02.3101. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219932 Review.
Cited by
- Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival.
Gong L, Peng J, Cui Z, Chen P, Han H, Zhang D, Leng X. Gong L, et al. Oncol Lett. 2010 Nov;1(6):1083-1088. doi: 10.3892/ol.2010.175. Epub 2010 Sep 22. Oncol Lett. 2010. PMID: 22870117 Free PMC article. - In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine.
Vilekar P, Awasthi V, Lagisetty P, King C, Shankar N, Awasthi S. Vilekar P, et al. BMC Immunol. 2010 Dec 10;11:60. doi: 10.1186/1471-2172-11-60. BMC Immunol. 2010. PMID: 21143974 Free PMC article. - DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
Gatto L, Di Nunno V, Tosoni A, Bartolini S, Ranieri L, Franceschi E. Gatto L, et al. Cancers (Basel). 2023 Jun 20;15(12):3251. doi: 10.3390/cancers15123251. Cancers (Basel). 2023. PMID: 37370860 Free PMC article. - Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.
Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Heuvers ME, et al. BMC Cancer. 2012 Dec 5;12:580. doi: 10.1186/1471-2407-12-580. BMC Cancer. 2012. PMID: 23217146 Free PMC article. Review. - Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.
Jadus MR, Natividad J, Mai A, Ouyang Y, Lambrecht N, Szabo S, Ge L, Hoa N, Dacosta-Iyer MG. Jadus MR, et al. Clin Dev Immunol. 2012;2012:160724. doi: 10.1155/2012/160724. Epub 2012 Jul 29. Clin Dev Immunol. 2012. PMID: 22899945 Free PMC article. Review.
References
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52. - PubMed
- Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–7. - PubMed
- Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9:684–93. - PubMed
- Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet. 1997;6:33–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials